Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Shares Outstanding (Diluted Average) (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Shares Outstanding (Diluted Average) for 4 consecutive years, with $135.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 18.56% to $135.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $135.7 million through Dec 2025, up 18.56% year-over-year, with the annual reading at $135.7 million for FY2025, 18.56% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $135.7 million at Centessa Pharmaceuticals, up from $133.6 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $135.7 million in Q4 2025, with the low at $90.5 million in Q1 2022.
  • Average Shares Outstanding (Diluted Average) over 4 years is $107.2 million, with a median of $98.0 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) increased 1.34% in 2023, then surged 33.18% in 2025.
  • Over 4 years, Shares Outstanding (Diluted Average) stood at $93.4 million in 2022, then increased by 2.97% to $96.2 million in 2023, then grew by 19.02% to $114.5 million in 2024, then rose by 18.56% to $135.7 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $135.7 million, $133.6 million, and $133.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.